Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niclosamide in Pediatric Relapsed/Refractory AML
NCT05188170Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of niclosamide in acute myeloid leukemia (AML) (4 arms), sponsored by Stanford University. Primary endpoint: Dose-limiting toxicity at 30 days. Started Nov 2022; status: recruiting.
02
Drugs
niclosamide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05188170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188170.